Boundless Bio Business Summary

Boundless Bio, Inc. (BOLD) is a clinical-stage oncology company pioneering the development of extrachromosomal DNA (ecDNA)-directed therapies (ecDTx) to treat oncogene-amplified tumors, which occur in approximately 14% to 17% of cancer patients. The company generates value through its proprietary Spyglass™ platform, which identifies synthetic lethal targets essential for ecDNA functionality, and its ECHO™ diagnostic tool for patient stratification. As of February 2026, Boundless Bio operates as a pre-revenue biotechnology firm, funding operations through equity financing and strategic realignments, such as the January 2026 decision to halt the POTENTIATE trial (BBI-355) to prioritize BBI-940, a first-in-class kinesin degrader entering Phase 1 clinical trials (KOMODO-1) for metastatic breast cancer. The company maintains a robust cash runway into the second half of 2028 and competes directly with oncology-focused firms like Agios Pharmaceuticals, Hummingbird Bioscience, and Lyell Immunopharma, as well as specialized players like Odyssey Therapeutics, positioning itself as the first and leading entity dedicated exclusively to the ecDNA therapeutic vertical. The company is led by a founding team and executive suite with a significant pedigree in precision oncology and successful exits. Zachary Hornby serves as President and CEO, bringing experience from Ignyta (acquired by Roche for $2 billion), where he was COO. The leadership team includes Chief Medical Officer Robert Doebele, M.D., Ph.D., co-founder of Rain Oncology and a pioneer in TRK inhibitor development, and Chief Scientific Officer Chris Hassig, Ph.D. The board is chaired by co-founder Jonathan Lim, M.D., the former CEO of Ignyta and a veteran biotech entrepreneur. Boundless Bio is backed by a high-profile syndicate of institutional investors, including ARCH Venture Partners, RA Capital Management, Nextech Invest, Wellington Management, and Leaps by Bayer, reflecting strong industry confidence in its novel approach to targeting previously undruggable cancer drivers.